Dr. Abou-Alfa Discusses New Treatment Options in HCC

Ghassan Abou-Alfa, MD
Published: Wednesday, Jan 09, 2019



Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the plethora of new treatment options in advanced hepatocellular carcinoma (HCC).

2018 was a breakthrough year for the previously stagnant field of HCC. Since 2007, there had only been 1 FDA-approved drug, sorafenib (Nexavar), which was followed by negative trial after negative trial. This past year, however, several new drugs have received FDA approval. Most recently, the TKI lenvatinib (Lenvima) was granted approval for use in the frontline setting, after having demonstrated noninferiority to sorafenib for overall survival in patients with unresectable HCC.

In the second-line setting, regorafenib (Stivarga) received FDA approval for patients who progress on sorafenib. The checkpoint inhibitor nivolumab (Opdivo) has a conditional FDA approval for the second-line setting as well, Abou-Alfa notes. Researchers will know more about the role of immunotherapy in this space when results from the CheckMate-459 study are read out in the near future; this trial is evaluating nivolumab head-to-head with sorafenib in patients with advanced HCC.

Cabozantinib (Cabometyx) and ramucirumab (Cyramza) also have indications for the second-line of treatment, he adds.
SELECTED
LANGUAGE


Ghassan K. Abou-Alfa, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the plethora of new treatment options in advanced hepatocellular carcinoma (HCC).

2018 was a breakthrough year for the previously stagnant field of HCC. Since 2007, there had only been 1 FDA-approved drug, sorafenib (Nexavar), which was followed by negative trial after negative trial. This past year, however, several new drugs have received FDA approval. Most recently, the TKI lenvatinib (Lenvima) was granted approval for use in the frontline setting, after having demonstrated noninferiority to sorafenib for overall survival in patients with unresectable HCC.

In the second-line setting, regorafenib (Stivarga) received FDA approval for patients who progress on sorafenib. The checkpoint inhibitor nivolumab (Opdivo) has a conditional FDA approval for the second-line setting as well, Abou-Alfa notes. Researchers will know more about the role of immunotherapy in this space when results from the CheckMate-459 study are read out in the near future; this trial is evaluating nivolumab head-to-head with sorafenib in patients with advanced HCC.

Cabozantinib (Cabometyx) and ramucirumab (Cyramza) also have indications for the second-line of treatment, he adds.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients With Graft-Versus-Host DiseaseMar 28, 20192.0
2017 Year in Review™: Clinical Impact of Immunotherapies in the Treatment of CancerMar 30, 20191.75
Publication Bottom Border
Border Publication
x